Pharmaceutical scientists from the National University of Singapore have developed multi-functional synthetic peptide nanonets for relieving inflammation caused by bacterial infection. This is achieved by concurrent trapping of bacterial endotoxins and pro-inflammatory cytokines.
Endotoxemia is characterised by the presence of endotoxins in the blood. These endotoxins can be released by gram-negative pathogens such as E. coli during systemic infections. When left unchecked, inflammatory host responses can result in extensive tissue damage and septic shock, which are associated with a high mortality rate.
Unfortunately, past research efforts to develop targeted therapies against sepsis have largely been unsuccessful due to the complex nature of interactions between pro- and anti-inflammatory mediators.
A more recent approach focuses on multi-cytokine for better management of septic complications. A research team led by Associate Professor Rachel Ee from the Department of Pharmacy under the NUS Faculty of Science has demonstrated that antibacterial peptide nanonets could possess additional functionalities to mitigate inflammatory responses which are commonly associated with bacterial infections.
These findings are built on their previous report of the design of anti-microbial peptides capable of in situ self-assembly into bacteria-trapping nanonets. Anti-inflammatory activity was achieved through the ability of the nanonets to bind and entrap endotoxins released by gram-negative pathogens, and inflammation mediators produced by host macrophages.
The cationic nanonets selectively entrapped pro-inflammatory cytokines while minimally binding the anti-inflammatory cytokines. The team achieved this desirable specificity by capitalising on the overall difference in net charge between these two different groups of cytokines.
These findings were published in the journal Advanced Healthcare Materials.
Additionally, the lipopolysaccharide (LPS)-binding effect resulted in the restoration of antimicrobial activity of colistin, a last-line therapy, against gram-negative pathogens.
Notably, this is the first reported instance of multi-functional peptide nanonets with long-ranging effects in alleviating the damages of septic complications at multiple stages. Biological evaluations of the peptide nanonets using an acute lung injury model demonstrated their efficacy in lowering the level of pro-inflammatory cytokines in the bronchoalveolar fluid of endotoxin-inoculated murine models. The resulting peptide effect was comparable to the control drug dexamethasone.
Prof Ee said, “Our peptide-based nanonets have shown unique therapeutic potential as a multi-functional biomaterial for holistic management of sepsis. Moving forward, we hope to continue their optimisation for clinical use.”